etf1 min
Vivozon的VVZ-2471完成韩国PHN二期临床最后受试者给药
发布: · 来源: mk.co.kr
一句$话总结: Vivozon Pharmaceutical关联公司Vivozon于12日表示，口服非阿片类镇痛候选药VVZ-2471在韩国针对带状疱疹后神经痛患者的二期临床中完成最后受试者给药。
广告
매일 5분 안에 핵심 뉴스
Vivozon Pharmaceutical关联公司Vivozon于12日表示，口服非阿片类镇痛候选物“VVZ-2471”在韩国针对带状疱疹后神经痛（PHN）患者的二期临床试验中，已完成对最后一名受试者的给药。本次临床是在韩国国内评估VVZ-2471用于PHN患者的二期研究。带状疱疹后神经痛被认为是带状疱疹后持续存在的神经病理性疼痛，公司一直推进该口服非阿片类镇痛候选物的开发。最后受试者给药完成意味着该临床阶段的主要程序已经结束，后续结果确认过程将受到关注。来源: mk.co.kr.
广告
매일 5분 안에 핵심 뉴스
Partner picks
Relevant partner links for this story
A lightweight commerce block designed to add monetization without breaking reading flow.
Coupang PartnersKR conversion
Good fit for Korea-based visitors ready to buy.
View offerAliExpressBudget picks
Works well for price-sensitive gadget and desk-tool traffic.
View offerAmazon AssociatesGlobal reach
Useful for books, work tools, and international shoppers.
View offerThis module may include affiliate links that earn a commission from qualifying purchases. ETF와이어
Sponsored
11개 언어 자동 번역
한 번 작성하면 11개 언어로 자동 노출
广告
Get notifications
